Legend Biotech Corporation

NASDAQ:LEGN

Biotechnology

Healthcare
$16.25 -13.51%

-$4.53 today

Market cap
$3.01B
Beta
0.35
P/E (TTM)
-21.4
EPS (TTM)
-$1.35
52W Low $16.24High $45.30

Volume 2.15M

Average 2.42M

LEGN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Legend Biotech CorporationNASDAQ: LEGN

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin widens to 58.9%

Gross margin was 58.9% in Q3 FY2026, up 1.3 pp from a year earlier. On a trailing-twelve-month basis it was 57.0%, down 3.6 pp year over year. Over 3 fiscal years it widened by 16.2 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
58.9%-5.6 pp QoQ
Last fiscal yearDec 2025
60.3%-2.3 pp YoY
LTMSep 2026
57.0%-3.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.3 pp——
1 year-2.3 pp——
3 years+16.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
60.3%
Year-over-year change
-2.3pp

Gross Margin vs competitors

How LEGN compares with its peers on the latest reported figures

  • LEGN's LTM Sep 2026 gross margin of 57.0% is the 6th highest of the 10 companies compared; the peer median is 81.9%.
  • Its year-over-year change of -3.6 pp is the 7th highest of 10, against a peer median of +0.5 pp.
  • Over three fiscal years its change of +16.2 pp compares with a peer median of -8.0 pp.
LEGN Competitors Peer median
Gross Margin for LEGN and competitors
Company Period LTM level YoY 3-year change
DTILPrecision BioSciences, Inc.LTM Mar 202697.0% -3.0 pp-8.0 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 202696.1% +15.9 pp+407.1 pp
IPSCCentury Therapeutics, Inc.FY202588.0% -12.0 pp-12.0 pp
CRBUCaribou Biosciences, Inc.LTM Mar 202682.6% +610.6 pp-6.4 pp
CLLSCellectis S.A.LTM Mar 202681.9% +0.5 pp+30.8 pp
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
AUTLAutolus Therapeutics plcLTM Mar 2026-11.2% +1636.4 pp-127.8 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-415.8% +126.5 pp-179.8 pp
RNACCartesian Therapeutics, Inc.LTM Mar 2026-621.0% -721.0 pp+1.8 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-7422.6% -7522.6 pp-32052.8 pp
ALLOAllogene Therapeutics, Inc.FY2025— ——
Peer median (excluding LEGN) 81.9%+0.5 pp-8.0 pp

Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue68.83M117.01M285.14M627.24M1.03B
Cost of Revenue065.36M144.21M234.58M408.1M
Gross Profit68.83M51.64M140.93M392.66M620.8M
Gross Margin100.0%44.1%49.4%62.6%60.3%
Research & Development313.35M335.65M382.22M413.54M414.7M
Selling, General & Admin149.5M174.05M200.93M284.26M341.6M
Operating Expenses461.11M507.26M580.41M695.9M757.3M
Depreciation & Amortization13.92M18.39M20.45M23.36M28.9M
EBITDA(392.38M)(416.54M)(477.87M)(113.16M)(232.3M)
EBITDA Margin-570.1%-356.0%-167.6%-18.0%-22.6%
Operating Income(392.29M)(455.62M)(439.49M)(303.24M)(136.5M)
Operating Margin-570.0%-389.4%-154.1%-48.3%-13.3%
Interest Income971K8.18M54.49M61.2M40.1M
Interest Expense900K10.8M21.79M21.62M21.4M
Other Income / Expenses(14.91M)9.9M(80.63M)145.11M(146.1M)
Income Before Tax(407.2M)(445.72M)(520.12M)(158.13M)(282.6M)
Pre-Tax Margin-591.6%-380.9%-182.4%-25.2%-27.5%
Income Tax Expense(3.61M)625K(1.86M)18.89M14.2M
Net Income(403.58M)(446.35M)(518.25M)(177.03M)(296.8M)
Net Margin-586.4%-381.5%-181.8%-28.2%-28.8%
EPS (Basic)(2.74)(2.81)(2.94)(0.97)(1.60)
EPS (Diluted)(2.74)(2.81)(2.94)(0.97)(1.60)
Weighted Avg Shares140.85M159.04M176.08M182.85M184.32M
Weighted Avg Shares (Diluted)140.85M159.04M176.08M182.85M184.32M

Legend Biotech Corporation

NASDAQ:LEGN

Intrinsic Alpha fair value

Locked

Current Price

$16.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.